Cohance Lifesciences Seeks Member Approval for Himanshu Agarwal's Whole-Time Director Appointment
Cohance Lifesciences is seeking member approval to appoint Mr. Himanshu Agarwal as Whole-Time Director and CFO for five years from October 29, 2025. E-voting is from December 24, 2025, to January 22, 2026. His remuneration includes fixed compensation of ₹3 Crores and variable compensation of ₹60 Lakhs for FY26, increasing from April 1, 2026.
The appointment of a Whole-Time Director, especially one also designated as CFO, is a significant management change that can impact the company's strategic direction and financial oversight. The detailed remuneration and tenure also contribute to the impact.
The announcement is a routine corporate action regarding the appointment of a Whole-Time Director and involves seeking member approval through a postal ballot. It does not contain significant positive or negative financial or operational news.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has issued a Postal Ballot Notice to its members seeking approval for the appointment of Mr. Himanshu Agarwal (DIN: 06672915) as a Whole-Time Director of the Company. This appointment, recommended by the Nomination and Remuneration Committee and approved by the Board on October 28, 2025, is effective from October 29, 2025, for a period of five years, concluding on October 28, 2030. Mr. Agarwal, who currently serves as the Chief Financial Officer, will also continue in that role. The remote e-voting period commences on Wednesday, December 24, 2025, at 9:00 a.m. (IST) and concludes on Thursday, January 22, 2026, at 5:00 p.m. (IST). The results of the postal ballot are expected to be declared on or before January 23, 2026.
Mr. Agarwal's remuneration has been detailed, with fixed compensation of ₹3 Crores per annum and variable compensation of ₹60 Lakhs per annum for the financial year 2025-26. From April 1, 2026, his fixed compensation will be revised to ₹3.56 Crores per annum, with variable compensation at ₹71 Lakhs per annum, subject to board-approved targets. The company also disclosed that Mr. Agarwal holds 7,79,092 unvested employee stock options. His profile highlights over 30 years of experience in finance, having previously worked with multinational corporations such as ICI India, Huhtamaki oyj, AkzoNobel India, and Astra Zeneca Pharma Ltd. He is a qualified Chartered Accountant, Cost and Management Accountant, and Company Secretary.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.